The US approval of Stribild is a big plus for the company's AIDS treatment franchise.
Top-line results show some hope for treatment even though a research goal was missed.
Perhaps everyone is feeling better about the economy -- at least enough to venture out of these sectors.
Shares of the world's largest drugmaker wobble from negative news on the company's Alzheimer's drug.
Stocks rise and the S&P manages to take and hold the 1,400 level, at least for now.
The entertainment giant is due to report after the close, and the satellite radio company's result topped expectations.
These picks earn top ratings for long-term growth, dividends, quality and value.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The offering could become the second-biggest this year if underwriters exercise an option to buy more shares.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.